论文部分内容阅读
伊马替尼除了选择性地抑制Abl酪氨酸激酶外,还抑制干细胞生长因子受体、血小板源性生长因子受体的酪氨酸激酶活性。后者功能的异常在Ph-的慢性骨髓增殖性疾病的发生发展中起着重要的作用,这为伊马替尼治疗Ph-的慢性骨髓增殖性疾病提供了理论基础。早期的临床试验表明,伊马替尼治疗真性红细胞增多症可减少部分患者对静脉放血的需要。对于常规治疗无效的慢性特发性骨髓纤维化伴髓样化生患者可试用伊马替尼。在慢性嗜酸性粒细胞白血病和高嗜酸性粒细胞综合征及相关的疾病中,伊马替尼治疗有效率为50％～80％。研究表明FIP1类似基因1与血小板源性生长因子受体α融合基因蛋白是其作用靶点之一。
In addition to selectively inhibiting Abl tyrosine kinase, imatinib also inhibits tyrosine kinase activity of stem cell growth factor receptor and platelet-derived growth factor receptor. The abnormal function of the latter plays an important role in the occurrence and development of Ph-chronic myeloproliferative diseases, which provides a theoretical basis for the treatment of Ph-chronic chronic myeloproliferative diseases with imatinib. Early clinical trials showed that imatinib treatment of polycythemia vera can reduce the need for venous blood in some patients. Imatinib may be tested in patients with chronic idiopathic myelofibrosis with myeloid metaplasia who are ineffective with conventional therapy. In chronic eosinophilic leukemia and hypereosinophilic syndromes and related diseases, imatinib treatment is effective at 50% to 80%. Studies have shown that FIP1-like gene 1 and platelet-derived growth factor receptor alpha fusion gene protein is one of its targets.